Skip to main content

Global AI in Pharmacovigilance Market on Track for Continuous Growth with a 12-15% CAGR by 2030

 


The AI in pharmacovigilance market is expected to grow at a CAGR of 12–15% from 2023 to 2030, driven by the need to automate adverse event data processing, stringent regulatory requirements, advancements in AI analytics, cost reduction benefits, and the increasing use of real-world evidence. These factors reshape pharmacovigilance processes, ensuring faster and more accurate safety assessments. However, high implementation costs and data privacy concerns pose challenges to the market growth.

Artificial intelligence (AI) in pharmacovigilance refers to applying machine learning, natural language processing, and other AI technologies to enhance the monitoring, detection, assessment, and prevention of adverse drug reactions and related issues. It helps streamline the traditionally manual processes involved in pharmacovigilance by automating data extraction, signal detection, and case processing. AI facilitates faster and more accurate analysis of large datasets, ensuring regulatory compliance and improving drug safety. The technology is particularly valuable in managing the complexities of real-world data, including unstructured information from medical records, social media, and adverse event reports.

Download a free sample report now 👉

https://meditechinsights.com/ai-in-pharmacovigilance-market/request-sample/

Growing Volume of Adverse Event Data

The increasing volume and complexity of adverse drug reaction (ADR) data are major factors driving the adoption of AI in pharmacovigilance. With the rise of global drug usage and access to various reporting channels, pharmacovigilance teams are overwhelmed by the sheer amount of structured and unstructured data generated daily. AI technologies, such as machine learning and natural language processing, enable efficient data extraction, deduplication, and classification from disparate sources, such as electronic health records, social media, and clinical trial databases. Automating these processes reduces human errors and ensures faster identification of potential safety signals, allowing quicker interventions. This capability is especially crucial as pharmaceutical companies face stringent timelines to comply with regulatory requirements and ensure public safety. By leveraging AI, the industry can handle data growth while maintaining cost efficiency and precision.

Integration of AI with Real-World Data Analytics

One significant advancement boosting the market is the integration of AI with real-world data (RWD) analytics in pharmacovigilance. RWD, sourced from electronic medical records, wearable devices, and patient registries, offers valuable insights into drug safety and efficacy in real-life settings. AI-powered algorithms can process and analyze these vast datasets to detect adverse drug reactions and patterns that might go unnoticed in clinical trials. Additionally, AI enables the identification of rare or long-term side effects through predictive modeling and signal detection. This integration enhances proactive safety monitoring, improves decision-making, and aids in personalized medicine approaches. As regulators increasingly recognize the importance of RWD in drug safety evaluations, the use of AI-driven RWD analytics has become a transformative force in the pharmacovigilance landscape, offering faster and more accurate results to safeguard patient health.

Competitive Landscape Analysis

The global AI in pharmacovigilance market is marked by the presence of established and emerging market players such as WNS, Accenture Plc, IQVIA Inc, Oracle, PAREXEL International Corporation, Cognizant and Aris Global among others. Some of the key strategies adopted by market players include new product development, strategic partnerships and collaborations, and geographic expansion.

Download a sample report for in-depth competitive insights

https://meditechinsights.com/ai-in-pharmacovigilance-market/request-sample/

Global AI in Pharmacovigilance Market Segmentation

This report by Medi-Tech Insights provides the size of the global AI in pharmacovigilance market at the regional- and country-level from 2023 to 2030. The report further segments the market based on component, deployment and end-user.

  • Market Size & Forecast (2023-2030), By Component, USD Million
    • Software
    • Services
  • Market Size & Forecast (2023-2030), By Deployment, USD Million
    • On-premises
    • Cloud-based
  • Market Size & Forecast (2023-2030), By End-user, USD Million
    • Pharmaceutical and Biotech Companies
    • Contract Research Organizations (CROs)
    • Others
  • Market Size & Forecast (2023-2030), By Region, USD Million
    • North America
      • US
      • Canada
    • Europe
      • UK
      • Germany
      • Italy
      • Spain
      • Rest of Europe
    • Asia Pacific
      • China
      • India
      • Japan
      • Rest of Asia Pacific
    • Latin America
    • Middle East & Africa

About Medi-Tech Insights

Medi-Tech Insights is a healthcare-focused business research & insights firm. Our clients include Fortune 500 companies, blue-chip investors & hyper-growth start-ups. We have completed 100+ projects in Digital Health, Healthcare IT, Medical Technology, Medical Devices & Pharma Services in the areas of market assessments, due diligence, competitive intelligence, market sizing and forecasting, pricing analysis & go-to-market strategy. Our methodology includes rigorous secondary research combined with deep-dive interviews with industry-leading CXO, VPs, and key demand/supply side decision-makers.

Contact:

Ruta Halde
Associate, Medi-Tech Insights
 +32 498 86 80 79
 info@meditechinsights.com 

Comments

Post a Comment

Popular posts from this blog

Global Biotechnology Market to grow at 13–15% CAGR as CRISPR use expands globally by 2029

  The global biotechnology market is set to witness a growth rate of 13-15% in the next 5 years.  Advancements in genetic engineering and genomics; growing demand for biopharmaceuticals; rising incidence of chronic diseases; growth in environmental and agricultural biotechnology; increased investment in R&D; growing demand for synthetic biology; and presence of favorable government initiatives are some of the key factors driving the biotechnology market. Biotechnology is the scientific field that uses biological organisms, systems, or processes to develop products and technologies aimed at improving health, agriculture, environmental sustainability, and industrial efficiency. By applying principles of genetics, molecular biology, and biochemistry, biotechnology enables advancements like genetic engineering, biopharmaceutical development, biofuels, and genetically modified organisms (GMOs). This field is instrumental in producing therapies for diseases, increasing crop r...
Post a Comment
Read more

Global Cell Isolation Market projected to grow at 11% CAGR with R&D in oncology therapies by 2030

  The global cell isolation market is projected to grow at a CAGR of 11% from 2025 to 2030,  driven by rising investments in cell-based research, increasing adoption of cell therapies, and growing demand for biopharmaceutical production. Growth is further supported by technological advancements in isolation methods, increasing R&D activities in regenerative medicine, and expanding clinical applications for isolated cells.  Cell isolation is a fundamental process in life sciences and clinical research, involving the separation of specific cell types from complex biological samples. The market is expanding due to growing applications in stem cell research, cancer biology, immunology, and personalized medicine. Additionally, improvements in magnetic-activated cell sorting (MACS), fluorescence-activated cell sorting (FACS), and microfluidic technologies are making cell isolation more efficient, reproducible, and scalable. To request a free sample copy of this report,...
Post a Comment
Read more

Global Multi Cancer Early Detection Market expanding 15–20% CAGR through personalized care 2030

  The multi cancer early detection market is expected to grow at a CAGR of around 15-20% during the forecast period.  This growth is primarily due to the rising awareness and increasing demand for early-stage screening tools, especially as cancer rates continue to rise globally, and technological advancements in screening methods. However, high costs and strict regulations can still hinder the market growth.  Multi Cancer Early Detection (MCED) refers to tests designed to detect multiple cancers, often from a single blood sample, unlike traditional methods, which can include multiple diagnostic tests or biopsies. These tests look for signs like DNA methylation patterns or small traces of tumor DNA floating in the bloodstream. The primary goal is early cancer detection, ideally before any symptoms appear, so the overall treatment is more effective and less expensive. Download a free sample report now 👉 https://meditechinsights.com/multi-cancer-early-detection-marke...
Post a Comment
Read more